on ORPHAN SYNERGY EUROPE-PHARMA (EPA:OSE)
OSE Immunotherapeutics: Reorganization of the Board of Directors
On September 30, 2025, OSE Immunotherapeutics held its Annual General Meeting in Paris. This event saw a complete renewal of its Board of Directors. Shareholders voted to appoint several members, including Caroline Mary, Pascale Briand, and Alexis Peyroles. Dr. Markus Cappel was elected Chairman of the Board of Directors.
Dr. Cappel, with thirty years of experience in biotechnology, expresses his enthusiasm for collaborating with the OSE Immunotherapeutics team to develop a robust pipeline of drug candidates. He notably played a key role in Amgen's acquisition of ChemoCentryx.
This reorganization aims to consolidate OSE Immunotherapeutics' position in the field of immunotherapy, a constantly evolving sector.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all ORPHAN SYNERGY EUROPE-PHARMA news